FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT in Adult and Paediatric Patients with AML or MDS By Ogkologos - March 13, 2025 870 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Smoking addiction killed my grandfather – now it’s up to the... December 29, 2022 A Rare Childbirth Complication Wiped This Woman’s Memory Of Giving Birth... December 4, 2019 Reunión anual de la American Society of Clinical Oncology de 2023:... June 2, 2023 New reports show staff shortages continue to hold back cancer care June 9, 2022 Load more HOT NEWS Zantac Contains A Cancer-Causing Chemical And Now Breast Cancer Patients Are... Woman Uses Passion For Crocheting To Help Cancer Patients, The Homeless... When He Said His Mother-In-Law Was Going To Live In The... Dame Deborah James’ incredible legacy: The Bowelbabe Fund announces first funded...
